Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention

Gallbladder carcinoma (GBC) is an uncommon and aggressive disease, which remains poorly defined at a molecular level. Here, we aimed to characterize the molecular landscape of GBC and identify markers with potential prognostic and therapeutic implications. GBC samples were analyzed using the MSK-IMP...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2022-12, Vol.28 (24), p.5359-5367
Hauptverfasser: Giraldo, Nicolas A, Drill, Esther, Satravada, Baby A, Dika, Imane El, Brannon, A Rose, Dermawan, Josephine, Mohanty, Abhinita, Ozcan, Kerem, Chakravarty, Debyani, Benayed, Ryma, Vakiani, Efsevia, Abou-Alfa, Ghassan K, Kundra, Ritika, Schultz, Nikolaus, Li, Bob T, Berger, Michael F, Harding, James J, Ladanyi, Marc, O'Reilly, Eileen M, Jarnagin, William, Vanderbilt, Chad, Basturk, Olca, Arcila, Maria E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 5367
container_issue 24
container_start_page 5359
container_title Clinical cancer research
container_volume 28
creator Giraldo, Nicolas A
Drill, Esther
Satravada, Baby A
Dika, Imane El
Brannon, A Rose
Dermawan, Josephine
Mohanty, Abhinita
Ozcan, Kerem
Chakravarty, Debyani
Benayed, Ryma
Vakiani, Efsevia
Abou-Alfa, Ghassan K
Kundra, Ritika
Schultz, Nikolaus
Li, Bob T
Berger, Michael F
Harding, James J
Ladanyi, Marc
O'Reilly, Eileen M
Jarnagin, William
Vanderbilt, Chad
Basturk, Olca
Arcila, Maria E
description Gallbladder carcinoma (GBC) is an uncommon and aggressive disease, which remains poorly defined at a molecular level. Here, we aimed to characterize the molecular landscape of GBC and identify markers with potential prognostic and therapeutic implications. GBC samples were analyzed using the MSK-IMPACT (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets) platform (targeted NGS assay that analyzes 505 cancer-associated genes). Variants with therapeutic implications were identified using OncoKB database. The associations between recurrent genetic alterations and clinicopathologic characteristics (Fisher exact tests) or overall survival (univariate Cox regression) were evaluated. P values were adjusted for multiple testing. Overall, 244 samples (57% primary tumors and 43% metastases) from 233 patients were studied (85% adenocarcinomas, 10% carcinomas with squamous differentiation, and 5% neuroendocrine carcinomas). The most common oncogenic molecular alterations appeared in the cell cycle (TP53 63% and CDKN2A 21%) and RTK_RAS pathways (ERBB2 15% and KRAS 11%). No recurrent structural variants were identified. There were no differences in the molecular landscape of primary and metastasis samples. Variants in SMAD4 and STK11 independently associated with reduced survival in patients with metastatic disease. Alterations considered clinically actionable in GBC or other solid tumor types (e.g., NTRK1 fusions or oncogenic variants in ERBB2, PIK3CA, or BRCA1/2) were identified in 35% of patients; 18% of patients with metastatic disease were treated off-label or enrolled in a clinical trial based on molecular findings. GBC is a genetically diverse malignancy. This large-scale genomic analysis revealed alterations with potential prognostic and therapeutic implications and provides guidance for the development of targeted therapies.
doi_str_mv 10.1158/1078-0432.CCR-22-1954
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9772093</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2725194679</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-fa3944906cfdb3f80b9680260174bef753b623345b2cc99fdff296158b433b2b3</originalsourceid><addsrcrecordid>eNpVkUtrFTEUx4MotlY_gpKlm6l5zkw2ggxaCxVF6jqcZJLeSCa5JnMv1E9vhj6oq3Pg_zghP4TeUnJOqRw_UDKMHRGcnU_Tz46xjiopnqFTKuXQcdbL521_8JygV7X-JoQKSsRLdMJ7xsbmPEW7KS_74nYu1XB0-FuOzh4iFDztoIBdXQl_YQ054ezxBcRoIsyzazoUG1JeAEOa8Y-8urQGiPgayo1bK_a54MvU8sdNyOk1euEhVvfmfp6hX18-X09fu6vvF5fTp6vOCkrXzgNXQijSWz8b7kdiVD8S1hM6COP8ILnpGedCGmatUn72nqm-fYgRnBtm-Bn6eNe7P5jFzbZdLxD1voQFyq3OEPT_Sgo7fZOPWg0DI4q3gvf3BSX_Obi66iVU62KE5PKhajYwSZXoB9Ws8s5qS661OP94hhK9UdIbAb0R0I2SZkxvlFru3dM3PqYesPB_M3qQmA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2725194679</pqid></control><display><type>article</type><title>Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Giraldo, Nicolas A ; Drill, Esther ; Satravada, Baby A ; Dika, Imane El ; Brannon, A Rose ; Dermawan, Josephine ; Mohanty, Abhinita ; Ozcan, Kerem ; Chakravarty, Debyani ; Benayed, Ryma ; Vakiani, Efsevia ; Abou-Alfa, Ghassan K ; Kundra, Ritika ; Schultz, Nikolaus ; Li, Bob T ; Berger, Michael F ; Harding, James J ; Ladanyi, Marc ; O'Reilly, Eileen M ; Jarnagin, William ; Vanderbilt, Chad ; Basturk, Olca ; Arcila, Maria E</creator><creatorcontrib>Giraldo, Nicolas A ; Drill, Esther ; Satravada, Baby A ; Dika, Imane El ; Brannon, A Rose ; Dermawan, Josephine ; Mohanty, Abhinita ; Ozcan, Kerem ; Chakravarty, Debyani ; Benayed, Ryma ; Vakiani, Efsevia ; Abou-Alfa, Ghassan K ; Kundra, Ritika ; Schultz, Nikolaus ; Li, Bob T ; Berger, Michael F ; Harding, James J ; Ladanyi, Marc ; O'Reilly, Eileen M ; Jarnagin, William ; Vanderbilt, Chad ; Basturk, Olca ; Arcila, Maria E</creatorcontrib><description>Gallbladder carcinoma (GBC) is an uncommon and aggressive disease, which remains poorly defined at a molecular level. Here, we aimed to characterize the molecular landscape of GBC and identify markers with potential prognostic and therapeutic implications. GBC samples were analyzed using the MSK-IMPACT (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets) platform (targeted NGS assay that analyzes 505 cancer-associated genes). Variants with therapeutic implications were identified using OncoKB database. The associations between recurrent genetic alterations and clinicopathologic characteristics (Fisher exact tests) or overall survival (univariate Cox regression) were evaluated. P values were adjusted for multiple testing. Overall, 244 samples (57% primary tumors and 43% metastases) from 233 patients were studied (85% adenocarcinomas, 10% carcinomas with squamous differentiation, and 5% neuroendocrine carcinomas). The most common oncogenic molecular alterations appeared in the cell cycle (TP53 63% and CDKN2A 21%) and RTK_RAS pathways (ERBB2 15% and KRAS 11%). No recurrent structural variants were identified. There were no differences in the molecular landscape of primary and metastasis samples. Variants in SMAD4 and STK11 independently associated with reduced survival in patients with metastatic disease. Alterations considered clinically actionable in GBC or other solid tumor types (e.g., NTRK1 fusions or oncogenic variants in ERBB2, PIK3CA, or BRCA1/2) were identified in 35% of patients; 18% of patients with metastatic disease were treated off-label or enrolled in a clinical trial based on molecular findings. GBC is a genetically diverse malignancy. This large-scale genomic analysis revealed alterations with potential prognostic and therapeutic implications and provides guidance for the development of targeted therapies.</description><identifier>ISSN: 1078-0432</identifier><identifier>ISSN: 1557-3265</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-22-1954</identifier><identifier>PMID: 36228155</identifier><language>eng</language><publisher>United States</publisher><subject>Adenocarcinoma - genetics ; Biomarkers, Tumor - genetics ; Carcinoma, Neuroendocrine ; Gallbladder Neoplasms - genetics ; Humans ; Mutation ; Prognosis</subject><ispartof>Clinical cancer research, 2022-12, Vol.28 (24), p.5359-5367</ispartof><rights>2022 American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-fa3944906cfdb3f80b9680260174bef753b623345b2cc99fdff296158b433b2b3</citedby><cites>FETCH-LOGICAL-c411t-fa3944906cfdb3f80b9680260174bef753b623345b2cc99fdff296158b433b2b3</cites><orcidid>0000-0003-0067-4198 ; 0000-0001-6723-2859 ; 0000-0001-9055-7213 ; 0000-0001-6608-345X ; 0000-0003-3882-5000 ; 0000-0002-3315-4538 ; 0000-0002-1635-5768 ; 0000-0002-0131-4904 ; 0000-0001-5824-6554 ; 0000-0001-6661-8733 ; 0000-0002-8076-9199 ; 0000-0002-1139-2914 ; 0000-0003-0227-3523 ; 0000-0002-1522-8054 ; 0000-0003-2747-1366 ; 0000-0002-3754-0321 ; 0000-0003-4267-4794 ; 0000-0002-8114-0237 ; 0000-0002-7452-1103 ; 0000-0001-8629-5732 ; 0000-0003-4610-0149 ; 0000-0002-6876-0482 ; 0000-0002-7029-4310</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3343,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36228155$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giraldo, Nicolas A</creatorcontrib><creatorcontrib>Drill, Esther</creatorcontrib><creatorcontrib>Satravada, Baby A</creatorcontrib><creatorcontrib>Dika, Imane El</creatorcontrib><creatorcontrib>Brannon, A Rose</creatorcontrib><creatorcontrib>Dermawan, Josephine</creatorcontrib><creatorcontrib>Mohanty, Abhinita</creatorcontrib><creatorcontrib>Ozcan, Kerem</creatorcontrib><creatorcontrib>Chakravarty, Debyani</creatorcontrib><creatorcontrib>Benayed, Ryma</creatorcontrib><creatorcontrib>Vakiani, Efsevia</creatorcontrib><creatorcontrib>Abou-Alfa, Ghassan K</creatorcontrib><creatorcontrib>Kundra, Ritika</creatorcontrib><creatorcontrib>Schultz, Nikolaus</creatorcontrib><creatorcontrib>Li, Bob T</creatorcontrib><creatorcontrib>Berger, Michael F</creatorcontrib><creatorcontrib>Harding, James J</creatorcontrib><creatorcontrib>Ladanyi, Marc</creatorcontrib><creatorcontrib>O'Reilly, Eileen M</creatorcontrib><creatorcontrib>Jarnagin, William</creatorcontrib><creatorcontrib>Vanderbilt, Chad</creatorcontrib><creatorcontrib>Basturk, Olca</creatorcontrib><creatorcontrib>Arcila, Maria E</creatorcontrib><title>Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Gallbladder carcinoma (GBC) is an uncommon and aggressive disease, which remains poorly defined at a molecular level. Here, we aimed to characterize the molecular landscape of GBC and identify markers with potential prognostic and therapeutic implications. GBC samples were analyzed using the MSK-IMPACT (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets) platform (targeted NGS assay that analyzes 505 cancer-associated genes). Variants with therapeutic implications were identified using OncoKB database. The associations between recurrent genetic alterations and clinicopathologic characteristics (Fisher exact tests) or overall survival (univariate Cox regression) were evaluated. P values were adjusted for multiple testing. Overall, 244 samples (57% primary tumors and 43% metastases) from 233 patients were studied (85% adenocarcinomas, 10% carcinomas with squamous differentiation, and 5% neuroendocrine carcinomas). The most common oncogenic molecular alterations appeared in the cell cycle (TP53 63% and CDKN2A 21%) and RTK_RAS pathways (ERBB2 15% and KRAS 11%). No recurrent structural variants were identified. There were no differences in the molecular landscape of primary and metastasis samples. Variants in SMAD4 and STK11 independently associated with reduced survival in patients with metastatic disease. Alterations considered clinically actionable in GBC or other solid tumor types (e.g., NTRK1 fusions or oncogenic variants in ERBB2, PIK3CA, or BRCA1/2) were identified in 35% of patients; 18% of patients with metastatic disease were treated off-label or enrolled in a clinical trial based on molecular findings. GBC is a genetically diverse malignancy. This large-scale genomic analysis revealed alterations with potential prognostic and therapeutic implications and provides guidance for the development of targeted therapies.</description><subject>Adenocarcinoma - genetics</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Carcinoma, Neuroendocrine</subject><subject>Gallbladder Neoplasms - genetics</subject><subject>Humans</subject><subject>Mutation</subject><subject>Prognosis</subject><issn>1078-0432</issn><issn>1557-3265</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUtrFTEUx4MotlY_gpKlm6l5zkw2ggxaCxVF6jqcZJLeSCa5JnMv1E9vhj6oq3Pg_zghP4TeUnJOqRw_UDKMHRGcnU_Tz46xjiopnqFTKuXQcdbL521_8JygV7X-JoQKSsRLdMJ7xsbmPEW7KS_74nYu1XB0-FuOzh4iFDztoIBdXQl_YQ054ezxBcRoIsyzazoUG1JeAEOa8Y-8urQGiPgayo1bK_a54MvU8sdNyOk1euEhVvfmfp6hX18-X09fu6vvF5fTp6vOCkrXzgNXQijSWz8b7kdiVD8S1hM6COP8ILnpGedCGmatUn72nqm-fYgRnBtm-Bn6eNe7P5jFzbZdLxD1voQFyq3OEPT_Sgo7fZOPWg0DI4q3gvf3BSX_Obi66iVU62KE5PKhajYwSZXoB9Ws8s5qS661OP94hhK9UdIbAb0R0I2SZkxvlFru3dM3PqYesPB_M3qQmA</recordid><startdate>20221215</startdate><enddate>20221215</enddate><creator>Giraldo, Nicolas A</creator><creator>Drill, Esther</creator><creator>Satravada, Baby A</creator><creator>Dika, Imane El</creator><creator>Brannon, A Rose</creator><creator>Dermawan, Josephine</creator><creator>Mohanty, Abhinita</creator><creator>Ozcan, Kerem</creator><creator>Chakravarty, Debyani</creator><creator>Benayed, Ryma</creator><creator>Vakiani, Efsevia</creator><creator>Abou-Alfa, Ghassan K</creator><creator>Kundra, Ritika</creator><creator>Schultz, Nikolaus</creator><creator>Li, Bob T</creator><creator>Berger, Michael F</creator><creator>Harding, James J</creator><creator>Ladanyi, Marc</creator><creator>O'Reilly, Eileen M</creator><creator>Jarnagin, William</creator><creator>Vanderbilt, Chad</creator><creator>Basturk, Olca</creator><creator>Arcila, Maria E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0067-4198</orcidid><orcidid>https://orcid.org/0000-0001-6723-2859</orcidid><orcidid>https://orcid.org/0000-0001-9055-7213</orcidid><orcidid>https://orcid.org/0000-0001-6608-345X</orcidid><orcidid>https://orcid.org/0000-0003-3882-5000</orcidid><orcidid>https://orcid.org/0000-0002-3315-4538</orcidid><orcidid>https://orcid.org/0000-0002-1635-5768</orcidid><orcidid>https://orcid.org/0000-0002-0131-4904</orcidid><orcidid>https://orcid.org/0000-0001-5824-6554</orcidid><orcidid>https://orcid.org/0000-0001-6661-8733</orcidid><orcidid>https://orcid.org/0000-0002-8076-9199</orcidid><orcidid>https://orcid.org/0000-0002-1139-2914</orcidid><orcidid>https://orcid.org/0000-0003-0227-3523</orcidid><orcidid>https://orcid.org/0000-0002-1522-8054</orcidid><orcidid>https://orcid.org/0000-0003-2747-1366</orcidid><orcidid>https://orcid.org/0000-0002-3754-0321</orcidid><orcidid>https://orcid.org/0000-0003-4267-4794</orcidid><orcidid>https://orcid.org/0000-0002-8114-0237</orcidid><orcidid>https://orcid.org/0000-0002-7452-1103</orcidid><orcidid>https://orcid.org/0000-0001-8629-5732</orcidid><orcidid>https://orcid.org/0000-0003-4610-0149</orcidid><orcidid>https://orcid.org/0000-0002-6876-0482</orcidid><orcidid>https://orcid.org/0000-0002-7029-4310</orcidid></search><sort><creationdate>20221215</creationdate><title>Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention</title><author>Giraldo, Nicolas A ; Drill, Esther ; Satravada, Baby A ; Dika, Imane El ; Brannon, A Rose ; Dermawan, Josephine ; Mohanty, Abhinita ; Ozcan, Kerem ; Chakravarty, Debyani ; Benayed, Ryma ; Vakiani, Efsevia ; Abou-Alfa, Ghassan K ; Kundra, Ritika ; Schultz, Nikolaus ; Li, Bob T ; Berger, Michael F ; Harding, James J ; Ladanyi, Marc ; O'Reilly, Eileen M ; Jarnagin, William ; Vanderbilt, Chad ; Basturk, Olca ; Arcila, Maria E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-fa3944906cfdb3f80b9680260174bef753b623345b2cc99fdff296158b433b2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adenocarcinoma - genetics</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Carcinoma, Neuroendocrine</topic><topic>Gallbladder Neoplasms - genetics</topic><topic>Humans</topic><topic>Mutation</topic><topic>Prognosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giraldo, Nicolas A</creatorcontrib><creatorcontrib>Drill, Esther</creatorcontrib><creatorcontrib>Satravada, Baby A</creatorcontrib><creatorcontrib>Dika, Imane El</creatorcontrib><creatorcontrib>Brannon, A Rose</creatorcontrib><creatorcontrib>Dermawan, Josephine</creatorcontrib><creatorcontrib>Mohanty, Abhinita</creatorcontrib><creatorcontrib>Ozcan, Kerem</creatorcontrib><creatorcontrib>Chakravarty, Debyani</creatorcontrib><creatorcontrib>Benayed, Ryma</creatorcontrib><creatorcontrib>Vakiani, Efsevia</creatorcontrib><creatorcontrib>Abou-Alfa, Ghassan K</creatorcontrib><creatorcontrib>Kundra, Ritika</creatorcontrib><creatorcontrib>Schultz, Nikolaus</creatorcontrib><creatorcontrib>Li, Bob T</creatorcontrib><creatorcontrib>Berger, Michael F</creatorcontrib><creatorcontrib>Harding, James J</creatorcontrib><creatorcontrib>Ladanyi, Marc</creatorcontrib><creatorcontrib>O'Reilly, Eileen M</creatorcontrib><creatorcontrib>Jarnagin, William</creatorcontrib><creatorcontrib>Vanderbilt, Chad</creatorcontrib><creatorcontrib>Basturk, Olca</creatorcontrib><creatorcontrib>Arcila, Maria E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giraldo, Nicolas A</au><au>Drill, Esther</au><au>Satravada, Baby A</au><au>Dika, Imane El</au><au>Brannon, A Rose</au><au>Dermawan, Josephine</au><au>Mohanty, Abhinita</au><au>Ozcan, Kerem</au><au>Chakravarty, Debyani</au><au>Benayed, Ryma</au><au>Vakiani, Efsevia</au><au>Abou-Alfa, Ghassan K</au><au>Kundra, Ritika</au><au>Schultz, Nikolaus</au><au>Li, Bob T</au><au>Berger, Michael F</au><au>Harding, James J</au><au>Ladanyi, Marc</au><au>O'Reilly, Eileen M</au><au>Jarnagin, William</au><au>Vanderbilt, Chad</au><au>Basturk, Olca</au><au>Arcila, Maria E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2022-12-15</date><risdate>2022</risdate><volume>28</volume><issue>24</issue><spage>5359</spage><epage>5367</epage><pages>5359-5367</pages><issn>1078-0432</issn><issn>1557-3265</issn><eissn>1557-3265</eissn><abstract>Gallbladder carcinoma (GBC) is an uncommon and aggressive disease, which remains poorly defined at a molecular level. Here, we aimed to characterize the molecular landscape of GBC and identify markers with potential prognostic and therapeutic implications. GBC samples were analyzed using the MSK-IMPACT (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets) platform (targeted NGS assay that analyzes 505 cancer-associated genes). Variants with therapeutic implications were identified using OncoKB database. The associations between recurrent genetic alterations and clinicopathologic characteristics (Fisher exact tests) or overall survival (univariate Cox regression) were evaluated. P values were adjusted for multiple testing. Overall, 244 samples (57% primary tumors and 43% metastases) from 233 patients were studied (85% adenocarcinomas, 10% carcinomas with squamous differentiation, and 5% neuroendocrine carcinomas). The most common oncogenic molecular alterations appeared in the cell cycle (TP53 63% and CDKN2A 21%) and RTK_RAS pathways (ERBB2 15% and KRAS 11%). No recurrent structural variants were identified. There were no differences in the molecular landscape of primary and metastasis samples. Variants in SMAD4 and STK11 independently associated with reduced survival in patients with metastatic disease. Alterations considered clinically actionable in GBC or other solid tumor types (e.g., NTRK1 fusions or oncogenic variants in ERBB2, PIK3CA, or BRCA1/2) were identified in 35% of patients; 18% of patients with metastatic disease were treated off-label or enrolled in a clinical trial based on molecular findings. GBC is a genetically diverse malignancy. This large-scale genomic analysis revealed alterations with potential prognostic and therapeutic implications and provides guidance for the development of targeted therapies.</abstract><cop>United States</cop><pmid>36228155</pmid><doi>10.1158/1078-0432.CCR-22-1954</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-0067-4198</orcidid><orcidid>https://orcid.org/0000-0001-6723-2859</orcidid><orcidid>https://orcid.org/0000-0001-9055-7213</orcidid><orcidid>https://orcid.org/0000-0001-6608-345X</orcidid><orcidid>https://orcid.org/0000-0003-3882-5000</orcidid><orcidid>https://orcid.org/0000-0002-3315-4538</orcidid><orcidid>https://orcid.org/0000-0002-1635-5768</orcidid><orcidid>https://orcid.org/0000-0002-0131-4904</orcidid><orcidid>https://orcid.org/0000-0001-5824-6554</orcidid><orcidid>https://orcid.org/0000-0001-6661-8733</orcidid><orcidid>https://orcid.org/0000-0002-8076-9199</orcidid><orcidid>https://orcid.org/0000-0002-1139-2914</orcidid><orcidid>https://orcid.org/0000-0003-0227-3523</orcidid><orcidid>https://orcid.org/0000-0002-1522-8054</orcidid><orcidid>https://orcid.org/0000-0003-2747-1366</orcidid><orcidid>https://orcid.org/0000-0002-3754-0321</orcidid><orcidid>https://orcid.org/0000-0003-4267-4794</orcidid><orcidid>https://orcid.org/0000-0002-8114-0237</orcidid><orcidid>https://orcid.org/0000-0002-7452-1103</orcidid><orcidid>https://orcid.org/0000-0001-8629-5732</orcidid><orcidid>https://orcid.org/0000-0003-4610-0149</orcidid><orcidid>https://orcid.org/0000-0002-6876-0482</orcidid><orcidid>https://orcid.org/0000-0002-7029-4310</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1078-0432
ispartof Clinical cancer research, 2022-12, Vol.28 (24), p.5359-5367
issn 1078-0432
1557-3265
1557-3265
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9772093
source MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Adenocarcinoma - genetics
Biomarkers, Tumor - genetics
Carcinoma, Neuroendocrine
Gallbladder Neoplasms - genetics
Humans
Mutation
Prognosis
title Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T08%3A42%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comprehensive%20Molecular%20Characterization%20of%20Gallbladder%20Carcinoma%20and%20Potential%20Targets%20for%20Intervention&rft.jtitle=Clinical%20cancer%20research&rft.au=Giraldo,%20Nicolas%20A&rft.date=2022-12-15&rft.volume=28&rft.issue=24&rft.spage=5359&rft.epage=5367&rft.pages=5359-5367&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-22-1954&rft_dat=%3Cproquest_pubme%3E2725194679%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2725194679&rft_id=info:pmid/36228155&rfr_iscdi=true